- Volume 16 Issue 9
DOI QR Code
Value of Combined Detection of Serum CEA, CA72-4, CA19-9 and TSGF in the Diagnosis of Gastric Cancer
- Yin, Li-Kui (Clinical Laboratory, Dong Ying People's Hospital) ;
- Sun, Xue-Qing (Clinical Laboratory, Dong Ying People's Hospital) ;
- Mou, Dong-Zhen (Department of Immune, Weifang Medical University)
- Published : 2015.05.18
Background: To explore whether combined detection of serum tumor markers (CEA, CA72-4, CA19-9 and TSGF) improve the sensitivity and accuracy in the diagnosis of gastric cancer (GC). Materials and Methods: An automatic chemiluminescence immune analyzer with matched kits were used to determine the levels of serum CEA, CA72-4, CA19-9 and TSGF in 45 patients with gastric cancer (GC group), 40 patients with gastric benign diseases (GBD group) hospitalized in the same period and 30 healthy people undergoing a physical examination. The values of those 4 tumor markers in the diagnosis of gastric cancer was analyzed. Results: The levels of serum CEA, CA72-4, CA19-9 and TSGF of the GC group were higher than those of the GBD group and healthy examined people and the differences were significant (P<0.001). The area under receiver operating characteristic (ROC) curves for single detection of CEA, CA72-4, CA19-9 and TSGF in the diagnosis of GC was 0.833, 0.805, 0.810 and 0.839, respectively. The optimal cutoff values for these 4 indices were 2.36 ng/mL, 3.06 U/mL, 5.72 U/mL and 60.7 U/mL, respectively. With combined detection of tumor markers, the diagnostic power of those 4 indices was best, with an area under the ROC curve of 0.913 (95%CI 0.866~0.985), a sensitivity of 88.9% and a diagnostic accuracy of 90.4%. Conclusions: Combined detection of serum CEA, CA72-4, CA19-9 and TSGF increases the sensitivity and accuracy in diagnosis of GC, so it can be regarded as the important means for early diagnosis.
Gastric cancer;tumor marker;carbohydrate antigen 72-4;carcino;embryonic antigen
- Choi AR, Park JC, Kim J, et al (2013). High level of preoperative carbohydrate antigen 19-9 is a poor survival predictor in gastric cancer. World J Gastroenterol, 19, 5302-8. https://doi.org/10.3748/wjg.v19.i32.5302
- Chen XJ, Li N, Huang YD, et al (2014). Factors for postoperative gallstone occurrence in patients with gastric cancer: a meta-analysis. Asian Pac J Cancer Prev, 15, 877-81. https://doi.org/10.7314/APJCP.2014.15.2.877
- Duraes C1, Almeida GM, Seruca R, et al (2014). Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? Virchows Arch, 464, 367-78. https://doi.org/10.1007/s00428-013-1533-y
- Femandes LC, Kin SB, Matos D (2005). Cytokeratins and carcinombryonic antigen in diagnosis staging and prognosis of colorectal adenocarconoma. World J Gastroenterol, 11, 548-55.
- Fernandes LC, Kin SB, Matos D (2005). Cytokeratins and carcinoembrayonic antigen in diagnosis, staging and prognosis of colorectal adenocarcinoma. World J Gastroenterol, 11, 548-55.
- Gwak HK1, Lee JH, Park SG (2014). Preliminary evaluation of clinical utility of CYFRA 21-1, CA 72-4, NSE, CA19-9 and CEA in stomach cancer. Asian Pac J Cancer Prev, 15, 4933-8. https://doi.org/10.7314/APJCP.2014.15.12.4933
- He CZ, Zhang KH, Li Q, et al (2013). Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer. BMC Gastroenterol, 13, 87. https://doi.org/10.1186/1471-230X-13-87
- Han ES, Lee HH, Lee JS, et al (2014). At which stage of gastric cancer progression do levels of carcinoembryonic antigen and carbohydrate antigen 19-9 increase? Application in advanced gastric cancer treatment. J Gastric Cancer, 14, 123-8. https://doi.org/10.5230/jgc.2014.14.2.123
- Jing JX, Wang Y, Xu XQ, et al (2014). Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer. Asian Pac J Cancer Prev, 15, 10267-72.
- Ji AJ, Liu SL, Ju WZ, et al (2014). Anti-proliferation effects and molecular mechanisms of action of tetramethypyrazine on human SGC-7901 gastric carcinoma cells. Asian Pac J Cancer Prev, 15, 3581-6. https://doi.org/10.7314/APJCP.2014.15.8.3581
- Jung KW, Won YJ, Kong HJ, et al (2013). Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res and Treat, 45, 1-14. https://doi.org/10.4143/crt.2013.45.1.1
- Li Y, Yang Y, Lu Y, et al (2014). Predictive value of CHFR and MLH1 methylation in human gastric cancer. Gastric Cancer, [Epub ahead of print].
- Lai H1, Jin Q, Lin Y, et al (2014). Combined use of lysyl oxidase, carcino-embryonic antigen, and carbohydrate antigens improves the sensitivity of biomarkers in predicting lymph node metastasis and peritoneal metastasis in gastric cancer. Tumour Biol, 35, 10547-54. https://doi.org/10.1007/s13277-014-2355-5
- Li XF, Liu AY, Li J (2015). Expression of MGMT, hMLH1 and XRCC1 in gastric cancer tissue and their clinical significance. J Int Transl Med, 3, 535-40.
- Liu J, Huang XE, Feng JF (2014). Further study on pemetrexed based chemotherapy in treating patients with advanced gastric cancer (AGC). Asian Pac J Cancer Prev, 15, 6587-90. https://doi.org/10.7314/APJCP.2014.15.16.6587
- Mattar R, Alves de Andrade CR, DiFavero GM, et al (2002). Preoperative serum levels of CA72-4, CEA, CA19-9 and alpha-fetoprotein in patients with gastric cancer. Rev Hosp Clin Fac Med Sao Paulo, 57, 89-92.
- Pan Z, Pang L, Ding B, et al (2013). Gastric cancer staging with dual energy spectral CT imaging. PLoS One, 8, 53651. https://doi.org/10.1371/journal.pone.0053651
- Park K, Jang G, Baek S, et al (2014). Usefulness of combined PET/CT to assess regional lymph node involvement in gastric cancer. Tumori, 100, 201-6.
- Reiter W, Stieber P, Reuter C, et al (2000). Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res, 20, 5195-8.
- Robertson DM, Pruysers E (2007). Jobling T. Inhibin in diagnosis for ovarian cancer. Cancer Len, 249, 14-7. https://doi.org/10.1016/j.canlet.2006.12.017
- Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA: A Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
- Tao XJ, Feng XH, Sun YF, et al (2012). Application of joint detection of CA 72-4, CA19-9, CA50 and CA242 in diagnosis of gastric cancer. Exp and Lab Med, 30, 169-71.
- Tian SB, Yu JC, Kang WM, et al (2014). Combined detection of CEA, CA 19-9, CA 242 and CA 50 in the diagnosis and prognosis of resectable gastric cancer. Asian Pac J Cancer Prev. 15, 6295-300. https://doi.org/10.7314/APJCP.2014.15.15.6295
- Whiting J, Sano T, Saka M, et al (2006). Follow-up of gastric cancer: a review. Gastric Cancer, 9, 74-81. https://doi.org/10.1007/s10120-006-0360-0
- Xu GH, Li Y, Li Y (2014). Expressions of SEL 1L and C-erbB-2 in Gastric Cancer Tissues and Its Clinical Significance. J Int Transl Med, 2, 318-21.
- Yang AP, Liu J, Lei HY, et al (2014). CA72-4 combined with CEA, CA125 and CA19-9 improves the sensitivity for the early diagnosis of gastric cancer. Clin Chim Acta, 437, 183-6. https://doi.org/10.1016/j.cca.2014.07.034
- Yun L, Bin Z, Guangqi G, et al (2014). Clinical significance in combined detection of serum pepsinogen I, pepsinogen II and carbohydrate antigen 242 in gastric cancer. Hepatogastroenterology, 61, 255-8.
- CdSe/ZnS Quantum Dot-Labeled Lateral Flow Strips for Rapid and Quantitative Detection of Gastric Cancer Carbohydrate Antigen 72-4 vol.11, pp.1, 2016, https://doi.org/10.1186/s11671-016-1355-3